Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

chiraag_19 93 posts  |  Last Activity: Jun 9, 2016 12:20 PM Member since: Mar 16, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    ICPT is the only player on the field.

    by biotechhead Jun 9, 2016 9:27 AM
    chiraag_19 chiraag_19 Jun 9, 2016 12:20 PM Flag

    Exactly...And here is the quote

    "And then the other question was, why do I believe that simtuzumab will work in liver fibrosis even though it hasn’t shown to be active in IPF myelofibrosis and in tumors. What a simple reason is you could make an argument and therefore fibrosis is different from IPL. Buy having that said it is somewhat liver fibrosis it’s different from IPF. But having that said, it somewhat diminishes my enthusiasm about simtuzumab, because it’s simply hasn’t shown any activity yet in any of the diseases that we chose to do"

    So Even Bischofberger think that this is a really a toss up now with deck stacked heavily against it. it is going to fail in both..mark it down.

  • Reply to

    ICPT is the only player on the field.

    by biotechhead Jun 9, 2016 9:27 AM
    chiraag_19 chiraag_19 Jun 9, 2016 11:16 AM Flag

    Gilead is looking into PSC with their simtuzumab. PSC is brother disease of PBC. SO if they success in PSC they will succeed in PBC as well.

  • Reply to

    ICPT is the only player on the field.

    by biotechhead Jun 9, 2016 9:27 AM
    chiraag_19 chiraag_19 Jun 9, 2016 11:09 AM Flag

    Again a lit. Here is the actual quote" CA is a bile acid and bile acids do many things in your body and side effects that we’re seeing the rash". FDA approved OCA for PBC...where Rash is actually one of the symptoms. So another lie for you.

    "There was also a side effect of reducing HDL fairly substantially and we have the philosophy instead of dealing with an orally absorbed systemically active bile acid analog we have an FXR agonist that’s minimally, orally absorbed that simply works into GI and releases FGF19."

    Again no words of bad safety profile. The drug will be absorbed in liver and guess where is the HDL/LDL is processed..in the liver. So where you have a targeted approach it wills till end up interfering the lipid processing if it hits the same pathway.

    Divray you are such a big lier and then you have audacity to claim that you are fact abased.

  • chiraag_19 chiraag_19 Jun 9, 2016 10:38 AM Flag

    And this is a blatant lie. He did not refer to any drug esp about OCA and never mentioned the safety profile.

    It's OK. Ultimately you have to do your own homework and be fine with your position. I'm good with my position

    Sentiment: Hold

  • Reply to

    Shorting here is a guaranteed loss

    by awesomeone1955 Jun 8, 2016 9:50 AM
    chiraag_19 chiraag_19 Jun 8, 2016 11:22 PM Flag

    I am not sure. Generally bioteck sector is looking up. Trump and CLlnton are tearing into each other so it is less policy and more barking. Oil money has been made. I would not short here because the risk is too high. Look at IBB for clues.

    Sentiment: Hold

  • Reply to

    Couple of observations

    by chiraag_19 Jun 8, 2016 10:34 AM
    chiraag_19 chiraag_19 Jun 8, 2016 11:00 AM Flag

    And Jonathan Silverstein is the managing partner of Orbimed who made this investment. He also has and I quote"1,259 shares of common stock and options to purchase 15,327 shares of common stock that are exercisable within 60 days of May 23, 2016 that are held directly by Mr. Silverstein. Look at the date 23rd May2016. Calculate 60 days from here that takes us to July 26th. If he exercises his right to buy you could bet your house that buyout is in process in next 2 months after July 26th .

    Sentiment: Hold

  • chiraag_19 by chiraag_19 Jun 8, 2016 10:34 AM Flag

    None of the insiders have sold any shares after approval. They could have easily timed it esp Dr. Shapiro. If you go back and look in the past every major run up has saw insiders esp Shapiro unloading few shares. That will tell you something.

    Second look at the ownership of the shares. Orbimed is almost a 55 owner and I'm delightfully surprise to see FMT with 14% ownership of share! That is again a vote of confidence.

    Third the pipeline is exciting. Look at harvoni/Sovaldi. Gilead made money of 1st Generation and the of 2nd generation and are right behind the 3rd generation combo. if there second molecule pans out they will have a long sustainable drug product with potential combination. Gilead also has atleast three other drugs that target other receptors in the same pathway so combinations are more likely to happen.

    i know some of you have been playing weekly buyout games. It will not do you good. You buy and hold your core and make money on trading your shares.

    buyout will happen before year end. My timeline is August/September when they have some idea on the new molecule is #$%$ and how the lipid studies are going on.

    If you are looking for buyout candidates here are coupleof nuggets. Always look for companies who have de-risked drugs that means they have done atleast phase 2 with a clear efficacy signal. Second they lack commercial infrastructure to launch drugs by themselves. third they have fewer competitors int he same disease with potential to launch in other indications. This applies to a lesser extend to oncology companies but still is true.

  • Reply to

    Seymour...where are u

    by drscottpalmer Jun 6, 2016 10:25 PM
    chiraag_19 chiraag_19 Jun 7, 2016 9:47 AM Flag

    Oh man....Sun will always set in west and Uling will always be there to defend Seymour.

    Sentiment: Hold

  • Reply to

    Question about pricing?

    by dip_199 Jun 3, 2016 9:24 AM
    chiraag_19 chiraag_19 Jun 3, 2016 1:58 PM Flag

    Also one critical problem with Provenge was the manufacturing cost. It was expensive and not any operating margin left int here to make any money. This will be a pill so easy. The real money make will be NASH. if it hits NASH, lipid trial shows no safety concern and the second compound is better than OCA then we can say this will be 500 dollar stock at minimum.

    Sentiment: Hold

  • Reply to

    Question about pricing?

    by dip_199 Jun 3, 2016 9:24 AM
    chiraag_19 chiraag_19 Jun 3, 2016 1:56 PM Flag

    People who have insurance and want to stay alive will pay the price. The good thing is insurance cover most of it. And people who don't have insurance can always go through charity and get the cost reduced.

    Sentiment: Hold

  • Reply to

    Question about pricing?

    by dip_199 Jun 3, 2016 9:24 AM
    chiraag_19 chiraag_19 Jun 3, 2016 1:54 PM Flag

    What! That is just a buffoonery argument you provided. Go back and check the cost of MS drugs as well as Oncology. Look at the total care that goes into costs. Insurance never pays what the list price is. It is always negotiated and to reduce the companies provide rebates.

    From your argument it is clear that you are a short or long Genfit. Good luck.

  • Reply to

    berens what a phony

    by what_a_manipulation Jun 2, 2016 3:44 PM
    chiraag_19 chiraag_19 Jun 2, 2016 4:01 PM Flag

    Not to mention KERX as well...

  • chiraag_19 by chiraag_19 Jun 2, 2016 4:00 PM Flag

    I think buyout is in works now. there is no worthy news except buyout

  • Reply to

    berens what a phony

    by what_a_manipulation Jun 2, 2016 3:44 PM
    chiraag_19 chiraag_19 Jun 2, 2016 3:59 PM Flag

    You should see his call with Relypsa. Andre Beren is having a really bad year. Relypsa and Intercept both showing him the door.

  • Reply to

    and for those that follow my picks

    by lerm14 Jun 2, 2016 12:08 PM
    chiraag_19 chiraag_19 Jun 2, 2016 12:37 PM Flag

    If somebody bought a stock based on yahoo message board post then well as they say " A fool and his money soon part". You cannot take research on yahoo whether be it long or short at face value. investing is all about knowing your risk and staying disciplined. Eventhough lerm is a pumper smart people can read his posts and realize that there is nothing there. Same goes for abalest.

    Sentiment: Hold

  • Reply to

    Mizuho upgrade coming PT likely $31

    by vs1234gs May 27, 2016 12:37 PM
    chiraag_19 chiraag_19 May 27, 2016 1:30 PM Flag

    Ask her how her Endo call is working before it blew up in her face. She talked to mgmt and gave a buy rating at $55 and change. After recent ENDO earning she was mad.....

  • Reply to

    Good label or Bad, it looks like

    by lerm14 May 26, 2016 11:22 AM
    chiraag_19 chiraag_19 May 27, 2016 10:16 AM Flag

    Is this your first rodeo buying bioteck stock with a binary event? Don't trade biotech stock and certainly not with emotions.

    Options are quick way of making money but it has its cons. And now you see here. I do hope that you make your money before your option expires.

    Sentiment: Hold

  • Reply to

    Annual meeting was short, nothing came out of it.

    by richard8547 May 25, 2016 12:19 PM
    chiraag_19 chiraag_19 May 26, 2016 10:20 AM Flag

    the very first thing I realized in investing is that msgboards where like minded people posts and gang up against person of opposite view ;)

    If yahoo posts would have affected stock price movement we would be all millionaire by now.

  • chiraag_19 chiraag_19 May 25, 2016 3:16 PM Flag

    We do...but unfortunately I'm convinced that there is no fundamental news that can move it out. The FDA approval is already baked in. 17-0 people..it is given. Just want to see the label.

    Sentiment: Hold

  • Reply to

    Annual meeting was short, nothing came out of it.

    by richard8547 May 25, 2016 12:19 PM
    chiraag_19 chiraag_19 May 25, 2016 3:13 PM Flag

    Thanks for the efforts Richard. I think for the first time in my 5 years of investing in biotech I came across a person who met BOD at annual meting and actually reported back what happened.

    I saw traders read your message and the stock is down :)

    Sentiment: Hold

CLDX
4.42+0.07(+1.61%)Jun 29 4:00 PMEDT